Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.
about
The emerging role of immunotherapy in colorectal cancerTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyDesign and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergiesAdvancing Cancer Therapy with Present and Emerging Immuno-Oncology ApproachesNovel Therapies in Development for Metastatic Colorectal Cancer.Biological Response Modifier in Cancer Immunotherapy.Cancer therapies in HIV cure research.Immunotherapy for colorectal cancer: where are we heading?The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.Natural Killer cells in HIV-1 infection and therapy.TLR Agonists as Adjuvants for Cancer Vaccines.Genuine Immunomodulation With dSLIM.Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context.Immunotherapy in colorectal cancer: for the select few or all?
P2860
Q28067898-D8AA5DD0-DCF9-4890-8D4D-9011DE616780Q28067939-2D0AC25B-F8F7-498B-A266-C48B521BCAB6Q35635250-7CE550CF-75EC-47A2-BEBA-384D6AE30572Q36777133-147972BB-DF50-4A01-9640-218FBF511859Q37596126-AC2CF543-AFB1-4D95-9EFB-3A988DBC196DQ38689153-9F748C2D-8C54-49F6-A765-1F3462CC99A3Q38800472-F74FC13B-4374-4148-9BDC-4BE67C236194Q38848213-52AA5CE4-1112-4C23-839C-81B260A79003Q38949445-182E3071-4A84-4A78-97BD-4E951B9E8099Q39218636-4DCE90DE-56CA-4D08-A46C-F5C83420AB1AQ40098403-E0A6E43B-CB03-48DC-B5C8-8885F2A5563FQ40280217-CE44DA72-4B6C-4BB9-B223-5141FB255C75Q40336664-651CFCC3-3857-4258-AA28-1472E49E40B3Q41934634-01B54B76-730C-4445-B471-5A8D24EAC211Q41997055-84D8B4EA-0315-4BCF-AA4D-C540D12C49A0Q42209151-8867C658-681F-4089-9586-CBD0F7D00626Q42359630-9E9E6E50-6542-4C5E-801B-F02FA6638C06Q55333223-106B25CB-3115-4D37-B9E6-F9AFB7899E2C
P2860
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Maintenance treatment with the ...... ind, placebo-controlled trial.
@ast
Maintenance treatment with the ...... ind, placebo-controlled trial.
@en
type
label
Maintenance treatment with the ...... ind, placebo-controlled trial.
@ast
Maintenance treatment with the ...... ind, placebo-controlled trial.
@en
prefLabel
Maintenance treatment with the ...... ind, placebo-controlled trial.
@ast
Maintenance treatment with the ...... ind, placebo-controlled trial.
@en
P2093
P2860
P921
P1476
Maintenance treatment with the ...... lind, placebo-controlled trial
@en
P2093
Burghardt Wittig
Dieter Nitsche
Frank Mayer
Hans-Joachim Schmoll
Hendrik Kroening
Johannes Andel
Jorge Riera-Knorrenschild
Reinhard Ziebermayr
Werner Scheithauer
P2860
P2888
P304
P356
10.1007/S00432-014-1682-7
P50
P577
2014-05-10T00:00:00Z